

CORPORATE OFFICE

Level 1
32 Oxford Terrace
Christchurch Central
CHRISTCHURCH 8011

Telephone: 0064 3 364 4160
Fax: 0064 3 364 4165
carolyn.gullery@cdhb.health.nz

10 May 2019

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]

[REDACTED]

RE Official Information Act request CDHB 10076

I refer to your email dated 9 April 2019 requesting the following information under the Official Information Act from Canterbury DHB. Specifically:

The number of clinical drug trials your DHB hosted in the 2017/2018 financial year + ongoing trials in 2019. Could figures please be broken-down by:

- 1. The number of sponsored clinical trials involving devices and pharmaceuticals.**

Our Research Team advise that there are 260 sponsored clinical trials in our system including Clinical, Evaluations, Observational, Qualitative and unclassified (other).

Please Note: This includes projects registered prior to 2017/18 that have subsequently become active. It will also include projects registered but not yet started.

- 2. Phase 1 first-man-in clinical trials and phase 2a/b safety and efficacy trials, phase 3 broader efficacy trials and phase 4 post-marketing surveillance. And whether these trials are investigator-initiated or industry-sponsored commercially contracted trials.**

To obtain this information would require a manual search of all 260 research projects, consequently we are declining this question under section 18(f) of the Official Information Act i.e. *"...the information cannot be made available without substantial collation or research"*.

- 3. Investigator-initiated studies of non-therapeutic interventions, e.g. new diagnostics or new applications of existing diagnostics.**
- 4. Investigator-initiated observational studies including epidemiologic studies.**

This information is not held in a central location and would require substantial time and resource to provide. We are therefore declining a response to these two questions under section 18(f) of the Official Information Act i.e. *"...the information cannot be made available without substantial collation or research"*.

5. Can you please also provide the aggregate income figure your DHB obtained from trials conducted in the 2017/2018 financial year.

Our total revenue (i.e. before expenditure) from Research & development activities was \$6.393M for the 2017/18 financial year as shown in our published annual accounts.

If you disagree with our decision to withhold information you may, under section 28(3) of the Official Information Act, seek an investigation and review of our decision from the Ombudsman. Information about how to make a complaint is available at www.ombudsman.parliament.nz; or Freephone 0800 802 602.

Please note that this response, or an edited version of this response, may be published on the Canterbury DHB website after your receipt of this response.

Yours sincerely

A handwritten signature in black ink, appearing to read 'Carolyn Gullery', with a long, sweeping underline.

Carolyn Gullery
Executive Director
Planning, Funding & Decision Support